产品: | ANGPTL3 抗体 |
货号: | DF6128 |
描述: | Rabbit polyclonal antibody to ANGPTL3 |
应用: | WB |
反应: | Human, Mouse, Rat |
预测: | Pig, Bovine, Horse, Sheep, Rabbit, Dog |
分子量: | 54kDa; 54kD(Calculated). |
蛋白号: | Q9Y5C1 |
RRID: | AB_2838095 |
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# DF6128, RRID:AB_2838095.
展开/折叠
ANG 5; ANG-5; ANG5; Angiopoietin 5; Angiopoietin like 3; Angiopoietin related protein 3; Angiopoietin-5; Angiopoietin-like protein 3; Angiopoietin-related protein 3; ANGL3_HUMAN; ANGPT5; ANGPTL3; ANL3; FHBL2; OTTHUMP00000010719; UNQ153/PRO179;
抗原和靶标
Expressed principally in liver. Weakly expressed in kidney. Binds to adipocytes. Increased expression and colocalization with activated ITGB3 in glomeruli of patients with nephrotic syndrome showing effaced podocyte foot processes (at protein level).
- Q9Y5C1 ANGL3_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKTFVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQEPTEISLSSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAIRPSNSQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEFWLGLEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVAITGNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNLNGKYNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFE
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - Q9Y5C1 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
S25 | Phosphorylation | Uniprot | |
N115 | N-Glycosylation | Uniprot | |
T206 | Phosphorylation | Uniprot | |
S207 | Phosphorylation | Uniprot | |
T226 | O-Glycosylation | Uniprot | |
N296 | N-Glycosylation | Uniprot | |
N357 | N-Glycosylation | Uniprot | |
S436 | Phosphorylation | Uniprot | |
S446 | Phosphorylation | Uniprot | |
T447 | Phosphorylation | Uniprot |
研究背景
Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol. Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity).
In vitro inhibits LPL activity; not effective on GPIHBP1-stabilized LPL.
Involved in angiogenesis. Binds to endothelial cells via integrin alpha-V/beta-3 (ITGAV:ITGB3), activates FAK, MAPK and Akt signaling pathways and induces cell adhesion and cell migration. Secreted from podocytes, may modulate properties of glomerular endothelial cells involving integrin alpha-V/beta-3 and Akt signaling. May increase the motility of podocytes. May induce actin filament rearrangements in podocytes implicating integrin alpha-V/beta-3 and Rac1 activation. Binds to hematopoietic stem cells (HSC) and is involved in the regulation of HSC activity probably implicating down-regulation of IKZF1/IKAROS (By similarity).
O-glycosylated at Thr-226 by GALNT2; blocks processing and activation by proprotein convertases.
In part proteolytically cleaved by proprotein convertases; proposed to be involved in activation.
Secreted. Cell projection>Lamellipodium.
Note: Colocalized with HSPG2 and activated ITGB3 on podocytes.
Expressed principally in liver. Weakly expressed in kidney. Binds to adipocytes. Increased expression and colocalization with activated ITGB3 in glomeruli of patients with nephrotic syndrome showing effaced podocyte foot processes (at protein level).
Interacts with ANGPTL8. Interacts with ITGB3 (By similarity).
The fibrinogen C-terminal domain is sufficient to mediate endothelial cell adhesion.
研究领域
· Organismal Systems > Digestive system > Cholesterol metabolism.
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.